Cover Image
Market Research Report
Product code 
1040242

Plasma Therapy Market by Type, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030

Published: | Allied Market Research | 214 Pages | Delivery time: 2-3 business days

Price

Back to Top
Plasma Therapy Market by Type, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030
Published: September 29, 2021
Allied Market Research
Content info: 214 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents
  • List of Tables

The global plasma therapy market was valued at $350.21 million in 2020 and is projected to reach $698.46 million by 2030 registering a CAGR of 8.50% from 2021 to 2030.

Blood is made up of white blood cells (WBCs), red blood cells (RBCs), plasma, and platelets. Plasma is the liquid part of blood, which is yellowish and holds blood cells. In plasma therapy, immunity of a healthy recovered individual can be transported to patients with assistance of plasma, as it comprises of high concentration of antibodies. Plasma therapy has been used for a long time, mainly in dentistry, dermatology, and orthopedics. Plasma treatment is usually used in wound healing, androgenetic alopecia, and facial restoration.

Factors such as rise in number of patients that are suffering from orthopedic disorders and androgenic alopecia further drive growth of the plasma therapy market in the coming years. Furthermore, increase in utilization of platelet-rich plasma in several therapeutic areas is further anticipated to propel the market growth. Furthermore, rise in incidences of arthritis is further estimated to propel growth of the plasma therapy market. On the other hand, dearth of reimbursement policies, different costs of plasma therapy, and limited utilization of PRP in patients suffering from diabetes and kidney ailments are further projected to hinder growth of the plasma therapy market during the forecast period.

The global plasma therapy market is segmented into type, application, end user, and region. Depending on type, the market is bifurcated into pure platelet-rich plasma, leukocyte-rich PRP, pure platelet-rich fibrin, and leukocyte-rich fibrin. The application segment is further categorized into orthopedics, dermatology, dentistry, and others.

On the basis of end user, it is segregated into hospitals, dermatology clinics, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the global plasma therapy market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps understand the applications and products of plasma therapy used across the globe.
  • Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

  • By Type
  • Pure Platelet-rich plasma (PRP)
  • Leukocyte-Rich PRP
  • Pure Platelet-Rich Fibrin
  • Leukocyte-Rich Fibrin
  • By Application
  • Orthopedics
  • Dermatology
  • Dentistry
  • Others
  • By End User
  • Hospitals
  • Dermatology Clinics
  • Others
  • By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
Product Code: LI_2114049 / A13680

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key Benefits for Stakeholders
  • 1.3.Key market segments
    • 1.3.1.List of key players profiled in the report
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five force analysis
  • 3.4.Top player positioning, 2020
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Surge in geriatric population across, coupled with rise in prevalence of rare diseases
      • 3.5.1.2.Increase in number of plasma collection centers across the globe
      • 3.5.1.3.Rise in the number of androgenic alopecia patients around the globe
    • 3.5.2.Restraint
      • 3.5.2.1.High cost of plasma derived products
    • 3.5.3.Opportunity
      • 3.5.3.1.High growth potential in emerging economies
    • 3.5.4.Impact analysis
  • 3.6.COVID-19 Impact analysis on the plasma therapy market

CHAPTER 4:PLASMA THERAPY MARKET, BY TYPE

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Platelet-rich plasma (PRP)
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
      • 4.2.2.1.Market size and forecast for pure platelet rich plasma by end users
    • 4.2.3.Market analysis, by country
  • 4.3.Leukocyte-Rich PRP
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast, by region
      • 4.3.2.1.Market size and forecast for leukocyte rich prp by end users
    • 4.3.3.Market analysis, by country
  • 4.4.Pure Platelet-Rich Fibrin
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast, by region
      • 4.4.2.1.Market size and forecast for leukocyte rich prp by end users
    • 4.4.3.Market analysis, by country
  • 4.5.Leukocyte-Rich Fibrin
    • 4.5.1.Key market trends, growth factors, and opportunities
    • 4.5.2.Market size and forecast, by region
      • 4.5.2.1.Market size and forecast for leukocyte rich fibrin by end users
    • 4.5.3.Market analysis, by country

CHAPTER 5:PLASMA THERAPY MARKET, BY APPLICATION

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Orthopedic
    • 5.2.1.Market size and forecast, by region
    • 5.2.2.Market analysis, by country
  • 5.3.Dermatology
    • 5.3.1.Market size and forecast, by region
    • 5.3.2.Market analysis, by country
  • 5.4.Dentistry
    • 5.4.1.Market size and forecast, by region
    • 5.4.2.Market analysis, by country
  • 5.5.Others
    • 5.5.1.Market size and forecast, by region
    • 5.5.2.Market analysis, by country

CHAPTER 6:PLASMA THERAPY MARKET, BY END USER

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Hospitals
    • 6.2.1.Market size and forecast, by region
    • 6.2.2.Market analysis, by country
  • 6.3.Dermatology Clinics
    • 6.3.1.Market size and forecast, by region
    • 6.3.2.Market analysis, by country
  • 6.4.Others
    • 6.4.1.Market size and forecast, by region
    • 6.4.2.Market analysis, by country

CHAPTER 7:PLASMA THERAPY MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends, growth factors, and opportunities
    • 7.2.2.Market size and forecast, by country
      • 7.2.2.1.U.S. plasma therapy market, by type
      • 7.2.2.2.U.S. plasma therapy market, by type
      • 7.2.2.3.U.S. plasma therapy market, by application
      • 7.2.2.4.U.S. plasma therapy market, end user
      • 7.2.2.5.Canada plasma therapy market
      • 7.2.2.6.Canada plasma therapy market, by type
      • 7.2.2.7.Canada plasma therapy market, by application
      • 7.2.2.8.Canada plasma therapy market, end user
      • 7.2.2.9.Mexico plasma therapy market
      • 7.2.2.10.Mexico plasma therapy market, by type
      • 7.2.2.11.Mexico plasma therapy market, by application
      • 7.2.2.12.Mexico plasma therapy market, end user
    • 7.2.3.North America market size and forecast, by type
    • 7.2.4.North America market size and forecast, by application
    • 7.2.5.North America market size and forecast, end user
  • 7.3.Europe
    • 7.3.1.Key market trends, growth factors, and opportunities
    • 7.3.2.Market size and forecast, by country
      • 7.3.2.1.Germany plasma therapy market
      • 7.3.2.2.Germany plasma therapy market, by type
      • 7.3.2.3.Germany plasma therapy market, by application
      • 7.3.2.4.Germany plasma therapy market, end user
      • 7.3.2.5.France plasma therapy market
      • 7.3.2.6.France plasma therapy market, by type
      • 7.3.2.7.France plasma therapy market, by application
      • 7.3.2.8.France plasma therapy market, end user
      • 7.3.2.9.UK plasma therapy market
      • 7.3.2.10.UK plasma therapy market, by type
      • 7.3.2.11.UK plasma therapy market, by application
      • 7.3.2.12.UK plasma therapy market, end user
      • 7.3.2.13.Italy plasma therapy market
      • 7.3.2.14.Italy plasma therapy market, by type
      • 7.3.2.15.Italy plasma therapy market, by application
      • 7.3.2.16.Italy plasma therapy market, end user
      • 7.3.2.17.Spain plasma therapy market
      • 7.3.2.18.Spain plasma therapy market, by type
      • 7.3.2.19.Spain plasma therapy market, by application
      • 7.3.2.20.Spain plasma therapy market, end user
      • 7.3.2.21.Rest of Europe plasma therapy market
      • 7.3.2.22.Rest of Europe plasma therapy market, by type
      • 7.3.2.23.Rest of Europe Plasma therapy market, by application
      • 7.3.2.24.Rest of Europe Plasma therapy market, end user
    • 7.3.3.Europe market size and forecast, by type
    • 7.3.4.Europe market size and forecast, application
    • 7.3.5.Europe market size and forecast, end user
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trends, growth factors, and opportunities
    • 7.4.2.Market size and forecast, by country
      • 7.4.2.1.Japan Plasma therapy market
      • 7.4.2.2.Japan Plasma therapy market, by type
      • 7.4.2.3.Japan Plasma therapy market, by application
      • 7.4.2.4.Japan Plasma therapy market, end user
      • 7.4.2.5.China Plasma therapy market
      • 7.4.2.6.China Plasma therapy market, by type
      • 7.4.2.7.China plasma therapy market, by application
      • 7.4.2.8.China plasma therapy market, end user
      • 7.4.2.9.Australia plasma therapy market
      • 7.4.2.10.Australia plasma therapy market, by type
      • 7.4.2.11.Australia plasma therapy market, by application
      • 7.4.2.12.Australia plasma therapy market, end user
      • 7.4.2.13.India plasma therapy market, by type
      • 7.4.2.14.India plasma therapy market, by type
      • 7.4.2.15.India plasma therapy market, by application
      • 7.4.2.16.India plasma therapy market, end user
      • 7.4.2.17.South Korea plasma therapy market
      • 7.4.2.18.South Korea plasma therapy market, by type
      • 7.4.2.19.South Korea plasma therapy market, by application
      • 7.4.2.20.South Korea plasma therapy market, end user
      • 7.4.2.21.Rest of Asia-Pacific plasma therapy market
      • 7.4.2.22.Rest of Asia-Pacific plasma therapy market
      • 7.4.2.23.Rest of Asia-Pacific plasma therapy market, by application
      • 7.4.2.24.Rest of Asia-Pacific plasma therapy market, end user
    • 7.4.3.Asia-Pacific market size and forecast, by type
    • 7.4.4.Asia-Pacific market size and forecast, by application
    • 7.4.5.Asia-Pacific market size and forecast, end user
  • 7.5.LAMEA
    • 7.5.1.Key market trends, growth factors, and opportunities
    • 7.5.2.Market size and forecast, by country
      • 7.5.2.1.Brazil plasma therapy market
      • 7.5.2.2.Brazil plasma therapy market, by type
      • 7.5.2.3.Brazil plasma therapy market, by application
      • 7.5.2.4.Brazil plasma therapy market, end user
      • 7.5.2.5.Saudi Arabia plasma therapy market
      • 7.5.2.6.Saudi Arabia plasma therapy market, by type
      • 7.5.2.7.Saudi Arabia plasma therapy market, by application
      • 7.5.2.8.Saudi Arabia plasma therapy market, end user
      • 7.5.2.9.South Africa plasma therapy market
      • 7.5.2.10.South Africa plasma therapy market, by type
      • 7.5.2.11.South Africa plasma therapy market, by application
      • 7.5.2.12.South Africa plasma therapy market, end user
      • 7.5.2.13.Rest of LAMEA plasma therapy market
      • 7.5.2.14.Rest of LAMEA plasma therapy market, by type
      • 7.5.2.15.Rest of LAMEA plasma therapy market, by application
      • 7.5.2.16.Rest of LAMEA plasma therapy market, end user
    • 7.5.3.LAMEA market size and forecast, by type
    • 7.5.4.LAMEA market size and forecast, by application
    • 7.5.5.LAMEA market size and forecast, end user

CHAPTER 8:COMPANY PROFILES

  • 8.1.Arthrex Inc.
    • 8.1.1.Company overview
    • 8.1.2.Operating business segments
    • 8.1.3.Product portfolio
  • 8.2.BTI Biotechnology Institute
    • 8.2.1.Company overview
    • 8.2.2.Operating business segments
    • 8.2.3.Product portfolio
  • 8.3.Exactech AG
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product portfolio
  • 8.4.Genesis Biologics Inc.
    • 8.4.1.Company overview
    • 8.4.2.Operating business segments
    • 8.4.3.Product portfolio
  • 8.5.Isto Biologics
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product portfolio
  • 8.6.JOHNSON & JOHNSON (DEPUY SYNTHES)
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segments
    • 8.6.4.Product Portfolio
    • 8.6.5.Business performance
  • 8.7.MUSCULOSKELETAL TRANSPLANT FOUNDATION
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product Portfolio
  • 8.8.Regen Lab SA
    • 8.8.1.Company overview
    • 8.8.2.Operating business segments
    • 8.8.3.Product portfolio
  • 8.9.TERUMO CORPORATION (Terumo BCT)
    • 8.9.1.Company overview
    • 8.9.2.Operating business segments
    • 8.9.3.Product portfolio
    • 8.9.4.Business performance
    • 8.9.5.Key strategic moves and developments
  • 8.10.ZIMMER BIOMET HOLDINGS, INC.,
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio
    • 8.10.5.Business performance

LIST OF TABLES

  • TABLE 01.PLASMA THERAPY MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 02.PLATELET-RICH PLASMA (PRP) MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 03.INDIRECT VENT MARKET, BY END USER, 2020-2030($MILLION)
  • TABLE 04.LEUKOCYTE-RICH PRP MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 05.LEUKOCYTE RICH PRP MARKET, BY END USER, 2020-2030($MILLION)
  • TABLE 06.PURE PLATELET-RICH FIBRIN MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 07.PURE PLATELET RICH MARKET, BY END USER, 2020-2030($MILLION)
  • TABLE 08.LEUKOCYTE-RICH FIBRIN MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 09.LEUKOCYTE RICH FIBRIN MARKET, BY END USER, 2020-2030($MILLION)
  • TABLE 10.PLASMA THERAPY MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 11.ORTHOPEDIC MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 12.DERMATOLOGY MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 13.DENTISTRY MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 14.OTHERS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 15.PLASMA THERAPY MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 16.HOSPITALS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 17.DERMATOLOGY CLINICS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 18.OTHERS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 19.PLASMA THERAPY MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 20.NORTH AMERICA PLASMA THERAPY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 21.U.S. PLASMA THERAPY MARKET, BY TYPE, 2020-2030
  • TABLE 22.U.S. PLASMA THERAPY MARKET, BY APPLICATION, 2020-2030
  • TABLE 23.U.S. PLASMA THERAPY MARKET, END USER, 2020-2030
  • TABLE 24.CANADA PLASMA THERAPY MARKET, BY TYPE, 2020-2030
  • TABLE 25.CANADA PLASMA THERAPY MARKET, BY APPLICATION, 2020-2030
  • TABLE 26.CANADA PLASMA THERAPY MARKET, END USER, 2020-2030
  • TABLE 27.MEXICO PLASMA THERAPY MARKET, BY TYPE, 2020-2030
  • TABLE 28.MEXICO PLASMA THERAPY MARKET, BY APPLICATION, 2020-2030
  • TABLE 29.MEXICO PLASMA THERAPY MARKET, END USER, 2020-2030
  • TABLE 30.NORTH AMERICA PLASMA THERAPY MARKET, BY TYPE, 2020-2030
  • TABLE 31.NORTH AMERICA PLASMA THERAPY MARKET, BY APPLICATION, 2020-2030
  • TABLE 32.NORTH AMERICA PLASMA THERAPY MARKET, END USER, 2020-2030
  • TABLE 33.EUROPE PLASMA THERAPY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 34.GERMANY PLASMA THERAPY MARKET, BY TYPE, 2020-2030
  • TABLE 35.GERMANY PLASMA THERAPY MARKET, BY APPLICATION, 2020-2030
  • TABLE 36.GERMANY PLASMA THERAPY MARKET, END USER, 2020-2030
  • TABLE 37.FRANCE PLASMA THERAPY MARKET, BY TYPE, 2020-2030
  • TABLE 38.FRANCE PLASMA THERAPY MARKET, BY APPLICATION, 2020-2030
  • TABLE 39.FRANCE PLASMA THERAPY MARKET, END USER, 2020-2030
  • TABLE 40.UK PLASMA THERAPY MARKET, BY TYPE, 2020-2030
  • TABLE 41.UK PLASMA THERAPY MARKET, BY APPLICATION, 2020-2030
  • TABLE 42.UK PLASMA THERAPY MARKET, END USER, 2020-2030
  • TABLE 43.ITALY PLASMA THERAPY MARKET, BY TYPE, 2020-2030
  • TABLE 44.ITALY PLASMA THERAPY MARKET, BY APPLICATION, 2020-2030
  • TABLE 45.ITALY PLASMA THERAPY MARKET, END USER, 2020-2030
  • TABLE 46.SPAIN PLASMA THERAPY MARKET, BY TYPE, 2020-2030
  • TABLE 47.SPAIN PLASMA THERAPY MARKET, BY APPLICATION, 2020-2030
  • TABLE 48.SPAIN PLASMA THERAPY MARKET, END USER, 2020-2030
  • TABLE 49.REST OF EUROPE PLASMA THERAPY MARKET, BY TYPE, 2020-2030
  • TABLE 50.REST OF EUROPE PLASMA THERAPY MARKET, BY APPLICATION, 2020-2030
  • TABLE 51.REST OF EUROPE PLASMA THERAPY MARKET, END USER, 2020-2030
  • TABLE 52.EUROPE PLASMA THERAPY MARKET, BY TYPE, 2020-2030
  • TABLE 53.EUROPE PLASMA THERAPY MARKET, APPLICATION, 2020-2030
  • TABLE 54.EUROPE PLASMA THERAPY MARKET, END USER, 2020-2030
  • TABLE 55.ASIA-PACIFIC PLASMA THERAPY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 56.JAPAN PLASMA THERAPY MARKET, BY TYPE, 2020-2030
  • TABLE 57.JAPAN PLASMA THERAPY MARKET, BY APPLICATION, 2020-2030
  • TABLE 58.JAPAN PLASMA THERAPY MARKET, END USER, 2020-2030
  • TABLE 59.CHINA PLASMA THERAPY MARKET, BY TYPE, 2020-2030
  • TABLE 60.CHINA PLASMA THERAPY MARKET, BY APPLICATION, 2020-2030
  • TABLE 61.CHINA PLASMA THERAPY MARKET, END USER, 2020-2030
  • TABLE 62.AUSTRALIA PLASMA THERAPY MARKET, BY TYPE, 2020-2030
  • TABLE 63.AUSTRALIA PLASMA THERAPY MARKET, BY APPLICATION, 2020-2030
  • TABLE 64.AUSTRALIA PLASMA THERAPY MARKET, END USER, 2020-2030
  • TABLE 65.INDIA PLASMA THERAPY MARKET, BY TYPE, 2020-2030
  • TABLE 66.INDIA PLASMA THERAPY MARKET, BY APPLICATION, 2020-2030
  • TABLE 67.INDIA PLASMA THERAPY MARKET, BY END USER, 2020-2030
  • TABLE 68.SOUTH KOREA PLASMA THERAPY MARKET, BY TYPE, 2020-2030
  • TABLE 69.SOUTH KOREAPLASMA THERAPY MARKET, BY APPLICATION, 2020-2030
  • TABLE 70.SOUTH KOREA PLASMA THERAPY MARKET, END USER, 2020-2030
  • TABLE 71.REST OF ASIA-PACIFIC PLASMA THERAPY MARKET, BY TYPE, 2020-2030
  • TABLE 72.REST OF ASIA-PACIFIC PLASMA THERAPY MARKET, BY APPLICATION, 2020-2030
  • TABLE 73.REST OF ASIA-PACIFIC PLASMA THERAPY MARKET, END USER, 2020-2030
  • TABLE 74.ASIA-PACIFIC PLASMA THERAPY MARKET, BY TYPE, 2020-2030
  • TABLE 75.ASIA-PACIFIC PLASMA THERAPY MARKET, BY APPLICATION, 2020-2030
  • TABLE 76.ASIA-PACIFIC PLASMA THERAPY MARKET, END USER, 2020-2030
  • TABLE 77.LAMEA PLASMA THERAPY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 78.BRAZIL PLASMA THERAPY MARKET, BY TYPE, 2020-2030
  • TABLE 79.BRAZIL PLASMA THERAPY MARKET, BY APPLICATION, 2020-2030
  • TABLE 80.BRAZIL PLASMA THERAPY MARKET, END USER, 2020-2030
  • TABLE 81.SAUDI ARABIA PLASMA THERAPY MARKET, BY TYPE, 2020-2030
  • TABLE 82.SAUDI ARABIA PLASMA THERAPY MARKET, BY APPLICATION, 2020-2030
  • TABLE 83.SAUDI ARABIA PLASMA THERAPY MARKET, END USER, 2020-2030
  • TABLE 84.SOUTH AFRICA PLASMA THERAPY MARKET, BY TYPE, 2020-2030
  • TABLE 85.SOUTH AFRICA PLASMA THERAPY MARKET, BY APPLICATION, 2020-2030
  • TABLE 86.SOUTH AFRICA PLASMA THERAPY MARKET, END USER, 2020-2030
  • TABLE 87.REST OF LAMEA PLASMA THERAPY MARKET, BY TYPE, 2020-2030
  • TABLE 88.REST OF LAMEA PLASMA THERAPY MARKET, BY APPLICATION, 2020-2030
  • TABLE 89.REST OF LAMEA PLASMA THERAPY MARKET, END USER, 2020-2030
  • TABLE 90.LAMEA PLASMA THERAPY MARKET, BY TYPE, 2020-2030
  • TABLE 91.LAMEA PLASMA THERAPY MARKET, BY APPLICATION, 2020-2030
  • TABLE 92.LAMEA PLASMA THERAPY MARKET, END USER, 2020-2030
  • TABLE 93.ARTHREX: COMPANY SNAPSHOT
  • TABLE 94.ARTHREX: OPERATING SEGMENTS
  • TABLE 95.ARTHREX: PRODUCT PORTFOLIO
  • TABLE 96.BTI: COMPANY SNAPSHOT
  • TABLE 97.BTI: OPERATING SEGMENTS
  • TABLE 98.BTI: PRODUCT PORTFOLIO
  • TABLE 99.EXACTECH: SNAPSHOT
  • TABLE 100.EXACTECH: OPERATING SEGMENTS
  • TABLE 101.EXACTECH: PRODUCT PORTFOLIO
  • TABLE 102.GENESIS BIOLOGICS: COMPANY SNAPSHOT
  • TABLE 103.GENESIS BIOLOGICS: OPERATING SEGMENTS
  • TABLE 104.GENESIS BIOLOGICS: PRODUCT PORTFOLIO
  • TABLE 105.ISTO BIOLOGICS: SNAPSHOT
  • TABLE 106.ISTO BIOLOGICS: OPERATING SEGMENTS
  • TABLE 107.ISTO BIOLOGICS: PRODUCT PORTFOLIO
  • TABLE 108.J&J: COMPANY SNAPSHOT
  • TABLE 109.J&J: Operating SEGMENTS
  • TABLE 110.J&J: PRODUCT PORTFOLIO
  • TABLE 111.MTF BIOLOGICS: COMPANY SNAPSHOT
  • TABLE 112.MTF BIOLOGICS: PRODUCT OFFERINGS
  • TABLE 113.MTF BIOLOGICS: PRODUCT PORTFOLIO
  • TABLE 114.REGENLAB: COMPANY SNAPSHOT
  • TABLE 115.REGENLAB: OPERATING SEGMENTS:
  • TABLE 116.REGENLAB: PRODUCT PORTFOLIO
  • TABLE 117.TERUMO: COMPANY SNAPSHOT
  • TABLE 118.TERUMO: OPERATING SEGMENTS
  • TABLE 119.TERUMO: PRODUCT PORTFOLIO
  • TABLE 120.ZIMMER BIOMET: COMPANY SNAPSHOT
  • TABLE 121.ZIMMER BIOMET: OPERATING SEGMENTS
  • TABLE 122.ZIMMER BIOMET: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.PLASMA THERAPY MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 04.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 05.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 06.HIGH THREAT OF NEW ENTRANTS
  • FIGURE 07.MODERATE INTENSITY OF RIVALRY
  • FIGURE 08.TOP PLAYER POSITIONING, 2020
  • FIGURE 09.IMPACT ANALYSIS
  • FIGURE 10.COMPARATIVE ANALYSIS OF PLATELET-RICH PLASMA (PRP) MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 11.COMPARATIVE ANALYSIS OF LEUKOCYTE-RICH PRP MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 12.COMPARATIVE ANALYSIS OF PURE PLATELET-RICH FIBRIN MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 13.COMPARATIVE ANALYSIS OF LEUKOCYTE-RICH FIBRIN MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 14.COMPARATIVE ANALYSIS OF ORTHOPEDIC MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 15.COMPARATIVE ANALYSIS OF DERMATOLOGY MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 16.COMPARATIVE ANALYSIS OF DENTISTRY MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 17.COMPARATIVE ANALYSIS OF OTHERS MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 18.COMPARATIVE ANALYSIS OF HOSPITALS MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 19.COMPARATIVE ANALYSIS OF DERMATOLOGY CLINICS MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 20.COMPARATIVE ANALYSIS OF OTHERS MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 21.J&J: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 22.J&J: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 23.J&J: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 24.TERUMO: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 25.TERUMO: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 26.TERUMO: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 27.ZIMMER BIOMET: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 28.ZIMMER BIOMET: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 29.ZIMMER BIOMET: REVENUE SHARE BY REGION, 2020 (%)